Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus best supportive care versus placebo as second-line treatment for hepatocellular carcinoma with elevated AFP after sorafenib
jRCT2080222919Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Ramucirumab + best supportive care with Placebo + best supportive care (2 arms). Started Jul 2015; status: completed.
02
Drugs
ramucirumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080222919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222919.